A pharmacoeconomic model will be developed to estimate the potential impact of IMBG in clinical outcomes and cost savings in the follow-up of patients with RA. Direct medical costs in RA are mainly driven by pharmacological treatment and disease activity.  The availability of IMBG can largely contribute to adequate the drug regimen for each patient to the individualized profile of sensitivity/resistance to DMARDs as shown in IMBG and can have a great potential for better clinical outcomes and cost savings.